A special National Institutes of Health oversight panel will no longer review all gene therapy applications and will instead take on a broader advisory role, as the treatment quickly becomes an established form of medical care with no extraordinary risks.
Providence Health and Services has been sued by a data analysis firm that claimed the 50-hospital system pushed its doctors to add complications or comorbidities to treatment documents so they could get higher Medicare reimbursement.
Advocacy groups sued to block Arkansas' Medicaid work requirement in federal court, two months after they won a federal ruling halting Kentucky's similar waiver program.
The American Hospital Association in September will launch its Center for Health Innovation, which aims to spread best practices across the membership. AHA Board Chair Nancy Howell Agee has been a key driver behind the association's efforts to address innovation.
HHS Secretary Alex Azar hinted the agency will overhaul certificate-of-need regulations and force drugmakers to pay full rebates to state Medicaid programs for new formulations of existing drugs.
The individual market is stable but expensive. As the government bears more of the cost, some industry and policy analysts question its long-term role in expanding coverage.
Rockwell Medical has hired a new CEO after reaching a settlement that includes $1.5 million in payments to two former top executives and two directors over disagreements on how to sell Triferic, the company's most promising drug.
State insurance regulators have expressed confusion and worry over the Trump administration's new rule expanding association plans, with some issuing emergency rules and guidances limiting their operations.
The FDA has noticeably shifted its approach to drug approval, releasing new recommendations that give drug developers a wider array of outcome measures to prove the efficacy of new medication-assisted treatments for opioid use disorder.
The CMS' payment formula in the first year places increased scrutiny on hospitals' charity care and bad debt reporting, but the agency isn't offering much detail on the audit process, which begins this fall.
Investors and journalists will be waiting to see if Tenet Project Japan will shed any more light on plans to sell off assets, Cardinal Health will report both its fourth-quarter and year-end results for fiscal 2018 and comments are due on proposed changes to the 2020 Census.
HHS announced it will maintain Title X family planning funding for all current grantees as well as 12 new program entrants amid Planned Parenthood's pending lawsuit over the Trump administration's new grant criteria.